GSK healthcare spin-off ViiV could generate one of the biggest IPOs in history: Here are some of the most successful corporate spin-offs stories October 22, 2014 ViiV Healthcare could generate one of the biggest IPOs in history, if GSK decides to go ahead and make it a spin-off company. The pharmaceutical firm was created in 2009 as a joint venture between GSK and US firm Pfizer. It specialises in developing therapies for HIV and operates in 16 countries. With [...]
GSK share price up despite Ebola vaccine delay: Head of research says it will be “too late” for this epidemic October 17, 2014 GlaxoSmithKline (GSK) has revealed that its Ebola vaccine won't be ready in time to deal with the current epidemic in west Africa. The British pharmaceutical giant started developing the vaccine earlier this year, in conjunction with the US National Institutes of Health. It uses a single protein from the Ebola virus to set off [...]
GSK confirms RBS’ Sir Philip Hampton as new chairman September 25, 2014 GlaxoSmithKline (GSK) has confirmed that Royal Bank of Scotland (RBS) chairman Sir Philip Hampton has been appointed to lead its board. The pharmaceutical giant said this morning that Hampton will join as non-executive director on 1 January next year, assuming the role of chairman from Sir Christopher Gent from 1 September. Although RBS did not [...]
GlaxoSmithKline to name Sir Philip Hampton chair September 24, 2014 SHARES in pharmaceutical giant GlaxoSmithKline (GSK) rose slightly in late afternoon trading yesterday after it emerged that Sir Philip Hampton was likely to be named as its new chairman. GSK is likely to announce Hampton’s move in the next two days – and with such a large job he is expected to eventually give up [...]
Share price up after rumours RBS’ Sir Philip Hampton “will be named GSK chairman before the weekend” September 24, 2014 Shares in pharmaceutical giant GlaxoSmithKline rose slightly in late afternoon trading after it emerged Sir Philip Hampton is likely to be named as its new chairman. Shares climbed 0.2 per cent to 1,425p, having spent the afternoon around the 1,418p mark. GSK is likely to announce Hampton's move in the next two days – such [...]
GSK share price shows immunity to Ebola vaccine September 17, 2014 The news GSK’s Ebola vaccine is to be trialled on humans failed to lift the company on the stock market this morning, with its share price falling 0.21 per cent to 1,438 pence. The experimental vaccine is to be tested on 60 healthy adults in Oxford, after it conferred resistance on a group of [...]
GSK share price falls, despite Ebola vaccine success September 8, 2014 Monkeys given an experimental Ebola vaccine developed by GSK were resistant to the deadly virus when infected with it five weeks later, trials have shown. The results of a drug trial, published in the journal Nature, show all of the monkeys not given the vaccine died within 6 days of infection, whereas the four [...]
GSK Ebola vaccine to be tested in UK August 28, 2014 An international consortium is fast-tracking an Ebola vaccine under development by the US National Institutes of Health (NIH) and GlaxoSmithKline, with human trials set to begin in the UK as early as September. The move follows a declaration by the World Health Organisation (WHO) that the Ebola outbreak in West Africa is a public [...]
GlaxoSmithKline to investigate fresh bribery claims in Syria August 12, 2014 GlaxoSmithKline is facing new bribery allegations in Syria, the latest in a string of accusations flung at the drugmaker from countries across the world. The FTSE 100-quoted company is accused of bribing Syrian doctors and officials to boost sales of its medicines, by offering cash, trips and free medical samples. The latest claims emerged after [...]
RBS chairman Sir Philip Hampton mulls move to head GlaxoSmithKline August 8, 2014 Sir Philip Hampton could jump ship to leading pharmaceutical firm GlaxoSmithKline after six years chairing RBS, it was reported yesterday. Neither is in any rush to replace its chairman – Glaxo’s chair Sir Christopher Gent expects to serve at the firm until the end of next year. He has served at the company for a [...]